Kodiak Sciences posts Q2 2026 net loss of $65.6M, cash $125.9M; DAYBREAK, PEAK readouts due Sept–Dec 2026
Kodiak Sciences reported a Q2 2026 net loss of $65.6M, or $1.05 per share, for the quarter ended June 30, 2026, and cash and cash equivalents of $125.9M. R&D rose to $56.1M. The company reiterated Phase 3 readouts: DAYBREAK in Sept 2026 and PEAK Pivotal Analysis 1 in Dec 2026.
How this was made
The 30-second read
Why it matters
Traders can update models for cash runway into 2027, burn intensity, and the calendar of upcoming Phase 3 topline catalysts that typically drive biotech valuation and options pricing.
Market read
Primary disclosure of quarterly financials and specific upcoming clinical milestones, useful for near-term positioning around biotech risk and funding expectations.
What to watch
The article highlights R&D and manufacturing activity ramp, but does not quantify trial cost per patient or any changes in enrollment pace beyond enrollment status, which could matter for runway and probability-of-success.
Background
Kodiak Sciences is advancing multiple Phase 3 programs in ophthalmology, including DAYBREAK (wet AMD), PEAK (macular edema secondary to inflammation), and ALTO (diabetic macular edema), while preparing for potential BLA submissions.
Ticker impact
Kodiak Sciences reported a Q2 2026 net loss of $65.6M, ended with $125.9M cash, and reiterated DAYBREAK and PEAK topline readouts.
Likely modest volatility around biotech risk appetite and cash-runway expectations, with direction dependent on how investors price the timing and likelihood of the next topline readouts.
This is a primary SEC 8-K style disclosure with concrete financials and specific upcoming trial milestones, but it does not include new efficacy results or guidance beyond reiterating timelines.
Market effects
Reinforces ongoing Phase 3 execution and burn profile for ophthalmology biotech, which can influence sentiment toward wet AMD and diabetic macular edema development programs.
Limited direct regional spillover; primarily affects US small/mid-cap biotech risk sentiment.
Moderate, as the programs target global ophthalmology markets but the article provides no cross-border regulatory or partnership updates.
Counterpoint
Investors may view the cash balance and reiterated timelines as evidence of controlled execution, making the next toplines the dominant driver rather than the current burn.
Key entities
- companyKodiak Sciences
Reported Q2 2026 net loss, cash balance, and reiterated Phase 3 topline readout timing for DAYBREAK and PEAK.
- clinical_programDAYBREAK
Phase 3 program with topline one-year primary endpoint results expected in September 2026.
- clinical_programPEAK
Phase 3 program with Pivotal Analysis 1 topline results expected in December 2026.
- clinical_programALTO
Phase 3 global superiority study enrollment initiated for diabetic macular edema versus aflibercept.
